Inactivation of the CDKN2/pl6 gene induced by methylation at 5′-CpG Island and its relation to lung cancer

  • Su Chang-qing 
  • Ye Yu-kun 
  • Wang Dong 
  • Shan Xiang-nian 
Basic Investigation


Objectives: To investigate the methylation status of the CDKN2/pl6 gene 5′-CpG island, and study the relationship between the CDKN2/pl6 gene inactivation by methylation and lung cancer. Methods: Genomic DNA extracted from the specimens of lung cancer and normal lung tissue was digested with methylation-sensitive endonucleases, and Southern blotting was used to analyze the methylation status of the CDKN2/pl6 gene in 89 cases of lung cancer and 10 cases of normal lung tissue. Results: In 89 cases of lung cancer studied, the CDKN2/pl6 gene was shown to be methylated in 21 cases with the total methylation rate of 23.6% (21/89), in which there were 15 cases (16.9%) methylated atSmaI sites, 12 cases (13.5%) atSmaI sites and 6 cases at bothSmaI andSacII sites. The methylation of the CDKN2/pl6 gene occurred in 17 among 42 of pl6 protein negative cases of lung cancer with a rate of 40.5% (17/42), and in 3 among 47 of pl6 protein positive cases with a rate of 6.4% (3/47). The CDKN2/pl6 gene was not methylated in 10 cases of normal lung tissue. Conclusion: The aberrant methylation of the CDKN2/pl6 gene 5′-CpG island is probably an important mechanism of the gene inactivation, it may be involved in the genesis and progress of lung cancer.

Key words

Lung neoplasm Tumor suppressor gene Methylation Restriction endonuclease Southern blotting 

CLC number



  1. [1]
    Kempster S, Phillips WA, Baindur-Hudson S, et al. Methylation of exon2 of pl6 is associated with late stage esophageal cancer [J]. Cancer Lett 2000; 150:57.PubMedCrossRefGoogle Scholar
  2. [2]
    Liggett WH Jr, Sidransky D. Role of the pl6 tumor suppressor gene in cancer [J]. J Clin Oncol 1998; 16:1197.PubMedGoogle Scholar
  3. [3]
    Gonzalez-Zulueta M, Bender CM, Yang AS, et al. Methylation of the 5′CpG island of the pl6/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing [J]. Cancer Res 1995; 55:4531.PubMedGoogle Scholar
  4. [4]
    Itoh N, Kakehe Y, Akao T, et al. Concomitant presence of P16/Cyclin-dependent kinase 4 and cyclin D/cyclin-dependent kinase 4 complexes in LNCaP prostatic cancer cell line [J]. Jpn J Cancer Res 1997; 88:229.PubMedGoogle Scholar
  5. [5]
    Stone S, Jiang P, Dayananth P, et al. Complex structure and regulation of the P16 (MTS1) locus [J]. Cancer Res 1995; 55:2988.PubMedGoogle Scholar
  6. [6]
    Migeon BR. Insights into X chromosome inactivation from studies of species variation DNA methylation and replication and vice versa [J]. Genet Res 1990; 56:91.PubMedCrossRefGoogle Scholar
  7. [7]
    Coleman A, Fountain JW, Nobori T, et al. Distinct deletion of chromosome 9p associated with melanoma versus glioma, lung cancer, and leukemia [J]. Cancer Res 1994; 54:344.PubMedGoogle Scholar
  8. [8]
    Quelle DE, Cheng M, Ashman R, et al. Cancer-associated mutations at the INK4a locus causes cell cycle arrest by pl6INK4a but not by the alternative reading frame protein pl9ARF [J]. Proc Natl Acad Sci USA 1997; 94:669.PubMedCrossRefGoogle Scholar
  9. [9]
    Herman JG, Merlo A, Mao L, et al. Inactivation of the CDKN2/pl6/MTSl gene is frequently associated with aberrant DNA methylation in all common human cancers [J]. Cancer Res 1995; 55:4525.PubMedGoogle Scholar
  10. [10]
    Mateos MV, Gonzalez M, Balanzategui A, et al. Status of methylation of pl6 gene in multiple myeloma: a comparative study of three methods for its detection [J]. Clin Biochem 2000; 33: 415.PubMedCrossRefGoogle Scholar
  11. [11]
    Lukas J, Aagaard L, Strauss M, et al. Oncogenic aberrations of P16INK4/CDKN2 and cyclinDl cooperate to deregulate Gl control [J]. Cancer Res 1995; 55:4818.PubMedGoogle Scholar
  12. [12]
    Grana X, Reddy EP. Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinase (cdks), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs) [J]. Oncogene 1995; 11:211.PubMedGoogle Scholar
  13. [13]
    Lo KW, Cheung ST, Leung SF, et al. Hypermethylation of the pl6 gene in nasopharyngeal carcinoma [J]. Cancer Res 1996; 56:2721.PubMedGoogle Scholar
  14. [14]
    Wong DJ, Barrett MT, Stoger R, et al. pl6INK4a promoter is hypermethylated at a high frequency in esophageal adenocarcinomas [J]. Cancer Res 1997; 57:2619.PubMedGoogle Scholar
  15. [15]
    Gonzalgo ML, Hayashida T, Bender CM, et al. The role of DNA methylation in expression of the pl9/pl6 locus in human bladder cancer cell lines [J]. Cancer Res 1998; 58:1245.PubMedGoogle Scholar
  16. [16]
    Akao T, Kakehi Y, Itoh N, et al. A high prevalence of functional inactivation by methylation modification of pl6INK4A/CDKN2/ MTS1 gene in primary urothelial cancers [J]. Jpn J Cancer Res 1997; 88:1078.PubMedGoogle Scholar
  17. [17]
    Herman JG, Civin CI, Issa JPJ, et al. Distinct patterns of inactivation of pl5INK4B and pl61NK4A characterize the major types of hematological malignancies [J]. Cancer Res 1997; 57:837PubMedGoogle Scholar
  18. [18]
    Zhang SJ, Endo S, Ichikawa T, et al. Frequent deletion and 5′CpG island methylation of the pl6 gene in primary malignant lymphoma of the brain [J]. Cancer Res 1998; 58:1231.PubMedGoogle Scholar

Copyright information

© Chinese Journal of Cancer Research 2001

Authors and Affiliations

  • Su Chang-qing 
    • 1
  • Ye Yu-kun 
    • 2
  • Wang Dong 
    • 2
  • Shan Xiang-nian 
    • 3
  1. 1.Department of Molecular BiologyCancer Center of the Chinese People’s Liberation Army (PLA), Nanjing 81st HospitalNanjing
  2. 2.Department of Cardiothoracic SurgeryCancer Center of the Chinese People’s Liberation Army (PLA), Nanjing 81st HospitalNanjing
  3. 3.Department of BiologyDongnan University Medical CollegeNanjing

Personalised recommendations